Search

Your search keyword '"Dermatologic agents -- Product development"' showing total 38 results
Start Over Descriptor "Dermatologic agents -- Product development" Journal plus company updates
38 results on '"Dermatologic agents -- Product development"'

1. Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Alumis Inc. a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated [...]

Published
2024

2. InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

BEIJING: INNOCARE PHARMA has issued the following news release: InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced [...]

Published
2024

3. Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Subjects
Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Cancer -- Care and treatment, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

MARLBOROUGH: Phio Pharmaceuticals Corp. has issued the following press release: Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLtm RNAi platform technology is designed to make [...]

Published
2023

4. InnoCare Reports First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

BEIJING: InnoCare Pharma , a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the first psoriasis patient has been dosed in clinical trial of the [...]

Published
2023

5. Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

Subjects
Dr. Reddy's Laboratories Ltd. -- Product development, Medical research, Medicine, Experimental, Skin diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Drug approval, Dermatologic agents -- Product development, Adults, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Oracea (Medication) -- Product development
Abstract

SCOTTSDALE: Journey Medical Corporation has issued the following press release: Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical'), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of [...]

Published
2023

6. Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Subjects
Dr. Reddy's Laboratories Ltd. -- Product development, Medical research, Medicine, Experimental, Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

SCOTTSDALE, Ariz: Journey Medical Corporation has issued the following news release: Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical'), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of [...]

Published
2023

7. Roivant surges 7% premarket as skin cream Vtama meets main goal of phase 3 eczema trial

Subjects
Atopic dermatitis, Toiletries industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Eczema, Skin, Dermatologic agents -- Product development, General interest, News, opinion and commentary, Vtama (Medication) -- Product development
Abstract

Dermavant Sciences' Vtama cream met the primary objective of clearer skin in a Phase 3 study in two-year-old and adult patients with atopic dermatitis (AD). Vtama is already approved in [...]

Published
2023

8. Vial Announced Enrollment of First Patient in Phase II Clinical Trial TLL018-205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll Pharmaceutical

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced that the first patient has been enrolled in the clinical trial TLL018-205, a Phase II, randomized, [...]

Published
2023

9. Can-Fite: Positive New Data from it's Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston

Subjects
Can-Fite BioPharma Ltd. -- Product development, Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: CAN-FITE BIOPHARMA LTD. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs [...]

Published
2022

10. Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles

Subjects
Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

WOBURN: Eirion has issued the following news release: Eirion Therapeutics Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial for the treatment of [...]

Published
2022

11. Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO, Calif.: Alumis Inc. has issued the following news release: Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today [...]

Published
2022

12. Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

Subjects
United States. Food and Drug Administration, Eye diseases, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

TEL AVIV, Israel & MELBOURNE, Australia: Azura Ophthalmics Ltd. has issued the following news release: Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics [...]

Published
2022

13. MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Subjects
Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Kidney diseases, General interest, News, opinion and commentary
Abstract

COPENHAGEN: MC2 Therapeutics has issued the following news release: MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for [...]

Published
2022

14. Dermavant to Present New Data from Phase 3 Trial Program of VTAMA(r) (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

Subjects
United States. Food and Drug Administration, Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Adults, Dermatologic agents -- Product development, General interest, News, opinion and commentary, Vtama (Medication) -- Product development
Abstract

LONG BEACH: DERMAVANT SCIENCES has issued the following news release: Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data [...]

Published
2022

15. Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress

Subjects
Can-Fite BioPharma Ltd. -- Product development, Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: CAN-FITE BIOPHARMA LTD. has issued the following news release: Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs [...]

Published
2022

16. Acute Bacterial Skin and Skin Structure Infections Pipeline Landscape Report 2022: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs

Subjects
Dermatology -- Formulae, receipts, prescriptions, Infection -- Health aspects, Skin -- Health aspects, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2022' clinical trials has been added to ResearchAndMarkets.com's offering. [...]

Published
2022

17. Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Industry hiring, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Lipidor has issued the following news release: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase [...]

Published
2022

18. Piclidenoson Destroys Pathological Skin Cells in Vitro Prior to Phase III Psoriasis Data Release, Can Fite Reports

Subjects
Can-Fite BioPharma Ltd. -- Product development, Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Skin, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

PETACH TIKVA: Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that pre-clinical studies with skin [...]

Published
2022

19. OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer Therapy Induced Skin Toxicity that Met Expectations

Subjects
Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Antineoplastic agents -- Product development, Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment -- Health aspects, Clinical trials -- Health aspects, Dermatologic agents -- Product development, Antimitotic agents -- Product development, General interest, News, opinion and commentary
Abstract

SEATTLE: OnQuality Pharmaceuticals has issued the following news release: OnQuality Pharmaceuticals ('OnQuality'), an oncology company developing targeted supportive therapies to address unmet needs in oncodermatology and oncogastroenterology (cancer therapy-induced side [...]

Published
2022

20. DICE Therapeutics, Inc. Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO, Calif.,; DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases [...]

Published
2021

21. Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary, Enstilar (Medication) -- Product development
Abstract

STOCKHOLM: Lipidor has issued the following news release: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate [...]

Published
2021

22. Arcutis Develops the first patient to be a potential treatment for scalp and body Psoria for phase 3 clinical trial of topical Roflumilast Foam (ARQ-154)

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Roflumilast -- Product development, General interest, News, opinion and commentary
Abstract

Arcutis Biotherapeutics, Inc. has enrolled the first patient in its single Phase 3 clinical trial evaluating topical roflumilast foam as a potential treatment for scalp and body psoriasis. Company is [...]

Published
2021

23. Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

LONG BEACH: DERMAVANT SCIENCES has issued the following news release: Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its [...]

Published
2021

24. Lipidor - Update on the Company's Phase III Clinical Trial of drug Candidate AKP02 for Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Lipidor AB publishers provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, [...]

Published
2021

25. Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer

Subjects
Oncology, Experimental, Skin cancer -- Care and treatment, Homeopathy -- Materia medica and therapeutics, Dermatology -- Formulae, receipts, prescriptions, Squamous cell carcinoma -- Care and treatment, Therapeutics -- Product development, Clinical trials, Dermatologic agents -- Product development, Cancer -- Research, General interest, News, opinion and commentary
Abstract

GAITHERSBURG: Sirnaomics, Inc. has issued the following news release: Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced [...]

Published
2020

26. European Rosacea Market Analysis 2020: Treatment Options, Late Stage Clinical Trials Pipeline and Market Forecasts to 2024

Subjects
Options (Finance) -- Product development, Dermatologic agents -- Product development, Epidemiology -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Europe Rosacea Market and Competitive Landscape - 2020' report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive [...]

Published
2020

27. Successful completion of feasibility study for the development of topical medical cannabis products based on AKVANO(r) technology

Subjects
Medical marijuana, Medical supplies -- Product development, Transdermal drug delivery systems -- Product development, Dermatologic agents -- Product development, Psoriasis -- Care and treatment, Product development, Time to market, General interest, News, opinion and commentary
Abstract

ASHDOD: Cannassure Therapeutics Ltd has issued the following news release: Cannassure Therapeutics Ltd (TASE: CSURE) ('Cannassure'), an Israel based developer and producer of innovative medical cannabis products, announces today the [...]

Published
2020

28. InventHelp Inventor Develops Skincare Product to Heal Skin and Keep it Healthy (TPA-2631)

Subjects
Skin diseases, Burns, Dermatologic agents -- Product development, Toiletries industry -- Product development, Skin, General interest, News, opinion and commentary
Abstract

PITTSBURGH: InventHelp has issued the following press release: 'I'm a doctor and I wanted to create a skincare solution to help heal a variety of problems and reduce signs of [...]

Published
2020

29. InventHelp Inventor Develops New Skin Care Product to Relieve Various Conditions (HTT-7334)

Subjects
Skin creams -- Product development, Skin diseases, Dermatologic agents -- Product development, Toiletries industry -- Product development, Skin, Toiletries -- Product development, General interest, News, opinion and commentary
Abstract

PITTSBURGH: InventHelp has issued the following news release: 'I have suffered from eczema for several years and thought there could be a better way to alleviate the symptoms,' said an [...]

Published
2020

30. Global Rosacea Market and Competitive Landscape 2020: Rosacea Late Stage Clinical Trials Pipelines, Drug Sales and Market Share by Country

Subjects
Options (Finance) -- Product development, Dermatologic agents -- Product development, Epidemiology -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Global Rosacea Market and Competitive Landscape - 2020' report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive [...]

Published
2020

31. Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis

Subjects
Clinical trials, Dermatologic agents -- Product development, Psoriasis -- Drug therapy, Therapeutics, General interest, News, opinion and commentary
Abstract

LONG BEACH: Dermavant has issued the following press release: Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the completion of patient [...]

Published
2020

32. InventHelp Inventor Develops Mess-Free Product Applicator (HTM-8235)

Subjects
Skin creams -- Product development, Dermatologic agents -- Product development, Toiletries industry -- Product development, Toiletries -- Product development, Skin, Backup software, Skin care products, General interest, News, opinion and commentary
Abstract

PITTSBURGH: InventHelp has issued the following news release: An inventor from Iron Mountain, Mich., has developed the ALL IN ONE MITT, a specially designed applicator for any kind of product [...]

Published
2020

33. Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

Subjects
Clinical trials, Atopic dermatitis -- Drug therapy, Dermatologic agents -- Product development, Psoriasis -- Drug therapy, Dermatitis, General interest, News, opinion and commentary
Abstract

Phoenix, Arizona: Dermavant Sciences, Inc. has issued the following press release: Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its [...]

Published
2019

34. BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

Subjects
Clinical trials, Dermatologic agents -- Product development, Minocycline, Skin, Pharmaceutical industry, Medical supplies, General interest, News, opinion and commentary
Abstract

SAN JOSE: BioPharmX Corporation has issued the following news release: BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it [...]

Published
2019

35. Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis

Subjects
Psoriasis, Clinical trials, Atopic dermatitis, Biotechnology industries -- Product development, Dermatologic agents -- Product development, Biotechnology, Dermatitis, Retirement benefits, General interest, News, opinion and commentary
Abstract

Massachusetts: Evelo Biosciences, Inc. has issued the following press release:Evelo Biosciences, Inc. (NASDAQ:EVLO) ('Evelo') a clinical-stage biotechnology company developing monoclonal microbials to engage immune cells in the small intestine and [...]

Published
2018

36. BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

Subjects
Clinical trials, Patient compliance, Dermatologic agents -- Product development, Product development, Time to market, General interest, News, opinion and commentary
Abstract

MENLO PARK : BioPharmX Corporation has issued the following press release: -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that [...]

Published
2018

37. BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea

Subjects
Clinical trials, Antibiotics -- Product development, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

MENLO PARK: BioPharmX Corporation has issued the following news release: BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced it has received [...]

Published
2018

38. Global Psoriasis Pipeline Drugs Market Assessment 2018-2023: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - ResearchAndMarkets.com

Subjects
Dermatologic agents -- Product development, Psoriasis -- Drug therapy, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023' report [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results